Pricing Log in Create free account

Genmab A/S Sponsored ADR (GMAB) vs Regeneron Pharmaceuticals, Inc. (REGN)

Genmab A/S Sponsored ADR and Regeneron Pharmaceuticals, Inc. are both Biotechnology companies. Regeneron Pharmaceuticals, Inc. is the larger, with a market value of $93.4B against $31.5B — 3.0× the size. Regeneron Pharmaceuticals, Inc. trades at the lower P/E: 19.2× against 41.7×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against 18.6%. Regeneron Pharmaceuticals, Inc. has the higher net margin (28.5% vs 19.1%) and the higher return on invested capital (11.6% vs 6.99%). Across the 21 metrics below, Regeneron Pharmaceuticals, Inc. leads on 17 and Genmab A/S Sponsored ADR on 4.

Valuation

Metric GMAB REGN Biotechnology median
P/E 41.72 19.22 10.26
P/S 7.87 5.44 9.18
P/B 5.46 2.74 2.05
Price to free cash flow n/m 25.31 24.81
EV/EBITDA 30.99 16.00 0.65
EV/Sales 8.75 5.09 8.98
Earnings yield 2.40% 5.20% (34.89%)
Free cash flow yield (19.53%) 3.95% (24.52%)

Profitability

Metric GMAB REGN Biotechnology median
Gross margin 93.03% 85.77% 65.16%
Operating margin 25.95% 28.79% 0.00%
Net margin 19.08% 28.51% 0.00%
Free cash flow margin (153.64%) 21.47% 0.00%
Return on equity 14.00% 14.95% (50.12%)
Return on assets 8.30% 11.39% (45.60%)
Return on invested capital 6.99% 11.61% 0.00%

Growth

Metric GMAB REGN Biotechnology median
Revenue growth (TTM) 22.26% 18.59% 6.26%
EPS growth (last fiscal year) (12.50%) 8.19% 29.88%
Revenue growth, 5-year CAGR 19.15% 11.04% 9.75%
Net income growth, 5-year CAGR 5.73% 5.10% 0.00%

Health

Metric GMAB REGN Biotechnology median
Debt to equity 0.86 0.06 0.00
Current ratio 2.46 3.35 4.89
Net debt to EBITDA 3.13 (1.43) 1.01

Dividend

Metric GMAB REGN Biotechnology median
Dividend yield — 0.41% 0.41%
Payout ratio — 0.08 —

Size

Metric GMAB REGN Biotechnology median
Market cap 31.51b 93.39b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack